All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CD22-Targeted CAR T Cells Elicit Responses With Acceptable Safety in Heavily Pretreated LBCL

August 3rd 2023

Matthew Frank, MD, PhD, discusses the rationale for evaluating CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma, important safety and efficacy data with this approach, next steps for this research, and how continued efforts may shed needed light on sequencing in this space.

Finding Fulfillment in Research and Patient Care

August 3rd 2023

Stephen T Magill, MD, PhD, details his inspirations behind entering not just the neuro-oncology and surgical treatment field, but also the arena of meningioma care and research; provides topline advice for current fellows looking to enter this field; and details current and ongoing research in this space taking place at Northwestern Medicine.

Stereotactic Radiation Strategies May Bolster RCC Multi-Modality Management Efforts

August 3rd 2023

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.

Data With Novel Agents Prompt Treatment Sequencing Discussions in MCL and CLL

August 3rd 2023

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

Investigation of Ubamatamab With or Without Cemiplimab Continues in Recurrent Ovarian Cancer

August 3rd 2023

The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.

Batiraxcept Plus Paclitaxel Misses PFS End Point in Platinum-Resistant Ovarian Cancer

August 3rd 2023

The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the phase 3 AXLerate-OC trial.

MD Anderson Names Christopher Flowers, MD, Division Head of Cancer Medicine

August 3rd 2023

The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, MD, an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search.

Gilteritinib/Chemotherapy Combination Safe and Effective in Newly Diagnosed AML

August 3rd 2023

The addition of the type 1 FLT3 inhibitor gilteritinib to induction and consolidation chemotherapy, followed by maintenance gilteritinib monotherapy, was safe and tolerable with promising initial efficacy in patients with newly diagnosed acute myeloid leukemia.

Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer

August 2nd 2023

Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.

Intravenous PRGN-3005 Plus Lymphodepletion Shows Early Promise in Ovarian Cancer

August 2nd 2023

Mary “Nora” Disis, MD, expands on key findings from the phase 1/1b study of PRGN-3005, discusses next steps for the trial, and explains how this research aids efforts to effectively utilize CAR T-cell therapy in ovarian cancer and other solid tumors.

Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors

August 2nd 2023

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.

Real-World Outcomes With Brexu-Cel Are Consistent With Clinical Data in R/R MCL, Regardless of Prior Treatment

August 2nd 2023

Swetha Kambhampati, MD, explains the need for real-world data on responses to brexu-cel in patients with relapsed/refractory MCL, compares safety and efficacy data from the subgroup analysis with prior results from ZUMA-2, and discusses how these findings support more long-term follow-up in this population.

FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in Previously Treated Metastatic Colorectal Cancer

August 2nd 2023

The FDA has approved trifluridine and tipiracil (Lonsurf) plus bevacizumab (Avastin) for patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; a VEGF inhibitor; and an EGFR inhibitor, if they have RAS wild-type disease.

Wealth of BTK Inhibitors Provides Tolerable, Individualized Treatment Options in CLL and MCL

August 2nd 2023

Prioty Islam, MD, MSc, reviews the benefits of using covalent BTK inhibitors in CLL and MCL; considerations for choosing first-generation vs next-generation covalent BTK inhibitors in patients with these B-cell malignancies; and the potential future role for ibrutinib in the CLL treatment paradigm.

Zipalertinib Shows Antitumor Activity and a Manageable Safety Profile in EGFR Exon 20+ NSCLC

August 2nd 2023

Zipalertinib demonstrated promising efficacy as well as an acceptable safety profile in heavily pretreated patients with recurrent or metastatic non–small cell lung cancer with EGFR exon 20 insertions.

Scientists Uncover Why Some Cells Become Resistant to Cancer Therapies

August 2nd 2023

Scientists develop ‘QR code for cancer cells,’ like tagging swans in a pond.

Talquetamab Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 2nd 2023

Carolina D. Schinke, MD, discusses key efficacy findings from the MonumenTAL-1 trial, adverse effects to be aware of with talquetamab, and what the findings from this trial reveal about the potential future for talquetamab and other bispecific antibodies in patients with multiple myeloma.

Mitomycin Gel May Have a Place in Chemo-Ablative Cytoreduction of Higher-Volume, Low-Grade UTUC

August 1st 2023

Patients with low-grade upper tract urothelial carcinoma experienced similar rendered disease free rates, regardless of surgery type or tumor volume, following treatment with mitomycin for pyelocalyceal solution.

FDA Grants Orphan Drug Designation to Elraglusib for Pancreatic Cancer

August 1st 2023

The FDA has granted orphan drug designation to the GSK-3β inhibitor, elraglusib, for the treatment of patients with pancreatic cancer.

Earlier-Line Pirtobrutinib Investigation May Alter BTK Inhibitor Sequencing in CLL and MCL

August 1st 2023

Prioty Islam, MD, MSc, discusses findings from the BRUIN trial, highlights the potential benefits of using noncovalent BTK inhibitors instead of or before covalent BTK inhibitors in patients with MCL or CLL, and previewed ongoing clinical trials investigating this class of agents in earlier treatment lines in these populations.